tradingkey.logo

Neogenomics Inc

NEO
查看詳細走勢圖
11.420USD
+0.150+1.33%
收盤 02/06, 16:00美東報價延遲15分鐘
1.47B總市值
虧損本益比TTM

Neogenomics Inc

11.420
+0.150+1.33%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.33%

5天

-5.31%

1月

-9.87%

6月

+98.26%

今年開始到現在

-2.89%

1年

-15.09%

查看詳細走勢圖

TradingKey Neogenomics Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Neogenomics Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療服務供應商行業排名29/75位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為13.50。中期看,股價處於平穩狀態。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Neogenomics Inc評分

相關信息

行業排名
29 / 75
全市場排名
159 / 4521
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Neogenomics Inc亮點

亮點風險
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
業績高增長
公司營業收入穩步增長,連續3年增長29.59%
估值高估
公司最新PE估值-12.87,處於3年歷史高位
機構減倉
最新機構持股134.68M股,環比減少5.47%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉434.19K股

分析師目標

基於 13 分析師
持有
評級
13.500
目標均價
+19.79%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Neogenomics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Neogenomics Inc簡介

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
公司代碼NEO
公司Neogenomics Inc
CEOZook (Antony P)
網址https://neogenomics.com/
KeyAI